PND2 BUDGET IMPACT ANALYSIS OF LEVETIRACETAM ADJUNCTIVE THERAPY IN PATIENTS WITH JUVENILE MYOCLONIC EPILEPSY IN SCOTLAND
Ryan J 1 , Germe M 2 , Brown M 3 1 Abacus International, Bicester, UK, 2 UCB, Braine-l'Alleud, Belgium, 3 UCB, Slough, UK OBJECTIVES: Juvenile myoclonic epilepsy (JME) is one of the most common epilepsy syndromes accounting for approximately 7% of all cases of epilepsy. Choosing an appropriate antiepileptic drug (AED) is essential for the proper management of JME because of the possibility of exacerbation of seizures by some AEDs and the adverse effect profiles of effective drugs. This study aims to estimate the incremental budgetary impact of introducing levetiracetam adjunctive therapy for JME patients in Scotland. METHODS: A budget impact model was built to estimate the additional costs or savings generated by the introduction of levetiracetam adjunctive therapy for JME patients. The model was designed from the Scottish NHS perspective for a 3-year time horizon. Prevalence and incidence data of epilepsy were obtained from published literature. Scottish population estimates were based on mid-2005 estimates from the General Register Office of Scotland (2006) . Levetiracetam adjunctive therapy was compared with topiramate adjunctive therapy. As resources used relating to general care, management of associated adverse events and of seizures were assumed to be the same for both adjunctive therapies, only drug acquisition costs were considered in this analysis. RESULTS: It is estimated that there are 2841 current cases and 142 new cases of JME each year. Based on levetiracetam market uptake, the number of patients with JME receiving levetiracetam is expected to be 28, 71, and 128 over the next 3 years. The incremental cost of using levetiracetam compared to topiramate adjunctive treatment is expected to be Յ5 per patient per year, resulting in an incremental budget impact of Յ156 to Յ698 over the next three years. This increase is mainly due to the increased market uptake of levetiracetam. CONCLUSION: Introducing levetiracetam adjunctive therapy for JME patients is predicted to have a limited impact on the Scottish NHS budget over a 3-year time period. 01.2006 -03.2007 . An assumption about 50% of patients with newly diagnosed Parkinson disease treatment with dopamine agonists was established. Estimates of the reimbursement costs when treatment of the eligible population were done taking into consideration three different scenarios: 1) Requip is reimbursed (6.68PLN per DDD) but no public coverage for Pronoran; 2) both drugs are reimbursed but reimbursement for Requip (4.59PLN per DDD) is limited by Pronoran (3.67PLN per DDD); and 3) both drugs are reimbursed and reimbursement level per DDD is the same in case of Pronoran and Requip (3.67PLN per DDD). Net budgetary effects for public payer were calculated when scenario: 2 or 3 was compared with scenario 1. All calculations were made for 2006 (1€ = 3.8PLN). RESULTS: Taking into account annual sales of the drugs and assumed that scenario 1 is replaced by scenario 2 it occurred that total savings for public payer in Poland were: 3530000PLN-10611000PLN (€ 923000-2792000) per year. In case of Pronoran and Requip were reimbursed and both had the same reimbursement level (3.67PLN per DDD) total savings for public payer in Poland would be: 4174000PLN-12522000PLN (€ 1098000-3295000) annually. CONCLUSION: Pronoran reimbursement in Poland lead to significant savings for public payer. The savings are especially high in case of the same reimbursement level per DDD for Pronoran and Requip.
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